Dr. Segar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3838 N Campbell Ave
Building 1
Tucson, AZ 85719Phone+1 520-694-2873
Summary
- I have a focus in treating patients with breast cancer. I'm involved in clinical trial research. I am also the director of the early phase trials program at University of Arizona Cancer Center
Education & Training
- University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2020
- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2014 - 2017
- Ross University School of MedicineClass of 2012
Certifications & Licensure
- AZ State Medical License 2016 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Roles: Contact
Publications & Presentations
PubMed
- 3 citationsFeasibility Trial to Evaluate Tendon Stiffness Obtained from Shear Wave Elastography Imaging as a Biomarker of Aromatase Inhibitor-Induced Arthralgias.Jessica A Martinez, Mihra S Taljanovic, Andres A Nuncio Zuniga, Betsy C Wertheim, Denise J Roe
Journal of Clinical Medicine. 2022-02-18 - 28 citationsComparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups:...Seongseok Yun, Nicole D. Vincelette, Jennifer Segar, Yimin Dong, Yang Shen
Clinical Lymphoma, Myeloma & Leukemia. 2016-06-01 - 7 citationsA Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.Jennifer Segar, Darien E Reed, Alison Stopeck, Robert B. Livingston, Pavani Chalasani
The Oncologist. 2019-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: